Plné znění - 19/2025 Sb.

Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

XXXXXXX

Xxxxxxxxxxxx zahraničních xxxx,

xxxxxx xx xxxx a xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx věcí č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;

Xxxxxxxxxxxx zahraničních xxxx xxxxxxx, že xxx 1. října 2023 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX oznámeno xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxx zakázaných xxxxx x xxxxx xxxxxxx xxx xxx 2024 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx úmluvy proti xxxxxxx xx sportu.

S xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx České xxxxxxxxx x prezident xxxxxxxxx xxxxxxxx listinu x xxxxxxx xxxx Xxxxxxx X Xxxxxx republikou.

Nové xxxxx Přílohy X xxxxxxxxx x platnost x souladu x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2024, pro Xxxxxx republiku vstoupilo x platnost dne 18. xxxxxx 2024 x xxxxxxxxx Xxxxxxx X pro xxx 2023, xxxxxxx xx 1. xxxxx 2023, xxxxx xxxxxxxxx x xxxxxxxx xxx Českou xxxxxxxxx xxx 22. xxxxxx 2023 a xxxx vyhlášena xxx č. 32/2023 Sb. m. s.

Xxxxxxxx znění Přílohy X pro rok 2024 x xxxx xxxxxxx do xxxxxxx xxxxxx se xxxxxxxxx xxxxxxxx.
&xxxx;

Xxxxxxx:

x z. JUDr. Xxxxxx, Xx.X., XX.X., x. x.

xxxxxx xxxxxxx xxxxx právní x xxxxxxxxxx
&xxxx;

Xxxxxxx č. 1

Překlad xxxxxxxxxxx xxxxxxx do xxxxxxx jazyka

Úvod

Seznam xxxxxxxxxx xxxxx x metod xxxxxxx je povinný Xxxxxxxxxxx xxxxxxxx x xxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx.

Xxxxxx xx xxxxxxxxxx xxxxxxxxxxxx po rozsáhlém xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxxx Xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx (XXXX). Xxxxxx xx xxxxxx xx 1. xxxxx 2024.

Oficiální text Xxxxxxx xxxxxxxxxx látek x metod bude xxxxxxxxx WADA x xxxx publikován x xxxxxxxxxx x xxxxxxxxxxxxx. X případě xxxxxxxxxxx xxxxxxxxxxxxx mezi anglickým x xxxxxxxxxxxx xxxxxx xxxxxxxxx xxxxx x xxxxxxxxxx.

Xxxx xxxx xxxxxxx xxxxxxx xxxxx xxxxxxxxx x xxxxx Xxxxxxx xxxxxxxxxx xxxxx x xxxxx.

Xxxxxxxx Xxx xxxxxxx

Xxxxx XXXX xxx xxxx xxxxx xxxxxxxxxxx xxxx xxxxxx, je xxxxxx Xxx soutěži x xxxxxx obdobím xxxxxxxxxxx xxxxx před půlnocí (xx 23:59 xxxxx) x xxx xxxxxxxxxxxxx Xxxxxxx, které se xx Sportovec xxxxxxxxx, xx xx xxxxx Xxxxxxx a xxxxxxx xxxxxx Xxxxxx.

Xxxxxxxx xxxxx

Xx xxxxxxx, xx daná xxxxx xxxx metoda xx zakázána Xxx xxxxxxx x Xxxx xxxxxx, jak xx xxxxxxxxxx x Xxxxxx.

Xxxxxxxxxx x Xxxxxxxxxxxx

Xxxxx článku 4.2.2 Světového xxxxxxxxxxxxxxx Xxxxxx „pro účely xxxxxxxx článku 10 xxxxx všechny Zakázané xxxxx Xxxxxxxxxxxx xxxxxxx, x xxxxxxxx těch xxxxxxxxxx x Xxxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx. Xxxxx Xxxxxxxx xxxxxx nebude Xxxxxxxxxxx xxxxxxx, pokud xxxx v Xxxxxxx xxxxxxxxx označena xxxx Xxxxxxxxxx xxxxxx.“ Xxxxx xxxxxxxxx k článku „Xxxxxxxxxx xxxxx x Xxxxxxxxxx metody uvedené x xxxxxx 4.2.2 xx neměly xxx xxxxxx xxxxxxxx xxxxxxxxxx xx méně důležité xxxx xxxx nebezpečné xxx jiné xxxxxxxxx xxxxx xxxx metody. Xxx spíše o xxxxx x metody, xxxxx Sportovec xxxxxxxxxxxxx xxxx nebo xxxxxx x xxxxxx účelu xxx ke xxxxxxxx xxxxxxxxxxx xxxxxx.“

Xxxxxxxx látky

Podle xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx látky xxxxxxxxxx xxxx xxxxx, xxxxx xxxx xxxx xxxxxx xxxxxxxx x xxxxxx xxxxxx xxxxxxx xxxxxxxxxx xx společnosti xxxx xxxxx sportu. Xxxx Návykové xxxxx xxxx označovány tyto xxxxx: xxxxxx, xxxxxxxxx (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (XXX).

X0 NESCHVÁLENÉ XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX I MIMO XXXXXX)

Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxxx xxxxxxxxxxxxxx xxxxx, xx xxxxxx xx nevztahuje xxxxx z xxxxxxxxxxxxx xxxxxx Xxxxxxx x xxxxx není v xxxxxxxx xxxx xxxxxxxxx xxxxxx vládním xxxxxxxxxxxxx xxxxxxxxxx orgánem pro xxxxxxx použití u xxxx (např. xxxxxx x xxxxxxxxxxxxx nebo xxxxxxxxx xxxxxx xxxx xxxxxxx xxxxx xxx xxxxxxx, xxxxxxxxxx xxxxx, xxxxx schválené xxxxx xxx xxxxxxxxxxx použití), xx xxxxxxxx stále.

Tato xxxxx xxxxxxxx mnoho xxxxxxx xxxxx, xxxx xxxx XXX-157, 2,4-xxxxxxxxxxxx (XXX) a xxxxxxxxxx xxxxxxxxx (xxxx. Reldesemtiv x Tirasemtiv).

S1 ANABOLICKÉ XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX I MIMO XXXXXX)

Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Nespecifické xxxxx.

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

X1.1. XXXXXXXXXX ANDROGENNÍ XXXXXXXX (XXX)

Xxx exogenním xxxxxx, xxxx xxxx xxxxxx:

•	1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx)	&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;	&xxxx;•&xxxx;	xxxxxxxxxx
•	1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxx (17ɑ-xxxxxx [1,2,5]oxadiazolo[3’,4’:2,3]-5ɑ-androstan-17ß-ol)
•	1-androsteron (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxx
•	1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxxx
•	1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx)		&xxxx;•	xxxxxxxxxx
•	4-xxxxxxxxxxxxxx (androst-4-en-3ß, 17ß-xxxx)		&xxxx;•	xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx)
•	4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx)		&xxxx;•	xxxxxxxxx
•	5-xxxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	7ɑ-xxxxxxx-XXXX		&xxxx;•	xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)
•	7ß-xxxxxxx-XXXX		&xxxx;•	xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx)
•	7-xxxx-XXXX		&xxxx;•	xxxxxxxxxxxxxx
•	11ß-xxxxx-19-xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx)
•	17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17ß-hydroxy-17ɑ-metylestr-4-en-3-on)
•	19-norandrostenediol (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxxxxxx
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxx (19-xxxxxxxxxxxxxx)
•	xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxxxxx (androst-4-en-3,17-dion)		•	norklostebol (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx
•	xxxxxxxx		&xxxx;•	xxxxxxxx
•	xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxx
•	xxxxxxxxx		&xxxx;•	xxxxxxxxxx
•	xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx)		&xxxx;•	xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)
•	xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx)		&xxxx;•	xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)
•	xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx x 17ɑ-xxxxx-5ɑ- androst-3-en-17ß- xx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxx		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx)		&xxxx;•	xxxxxxxxxxx
•	xxx-xxxxxxxxxxxxxxxxxx (17β-xxxxxxx-5β-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxx
•	xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx)		&xxxx;•	xxxxxxxxx (17β-hydroxyestr-4,9,11-trien-3-on)
•	fluoxymesteron		•	trestolon (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX)

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými účinky.

S1.2. XXXXXXX ANABOLICKÉ XXXXX

Xxxx xxxx xxxxxx:

Xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx receptorů [XXXX, xxxx. xxxxxxx, enobosarm (xxxxxxx), LGD-4033 (xxxxxxxxx), XXX140, X-23 x XX-11], zeranol a xxxxxxxxxx.

X2 PEPTIDOVÉ XXXXXXX, XXXXXXX FAKTORY, XXXXXXXX XXXXX X MIMETIKA

ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx v xxxx xxxxx xxxx Xxxxxxxxxxxx látky.

Následující látky x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx.

X2.1. ERYTROPOETINY (XXX) X LÁTKY OVLIVŇUJÍCÍ XXXXXXXXXXX

Xxxx xxxx xxxxxx:

X2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx receptorů, xxxx. xxxxxxxxxxxx (dEPO); xxxxxxxxxxxxx (XXX); sloučeniny xxxxxxxx na XXX, [xxxx. XXX-Xx, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)]; XXX- xxxxxxxxx xxxxxxxxxx x xxxxxx sloučeniny, xxxx. XXXX-530, xxxxxxxxxxx.

X2.1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (HIF), např. xxxxxx; xxxxxxxxxxx (XXX1278863); XXX2; xxxxxxxxxx (XXX 85-3934); roxadustat (XX-4592); xxxxxxxxxx (XXX-6548); xxxxx.

X2.1.3 Xxxxxxxxxx XXXX, např. X-11706.

X2.1.4 Xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxx (XXX-β), xxxx. xxxxxxxxxxxx; xxxxxxxxxxx.

X2.1.5 Agonisté xxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxx. xxxxxx XXX; xxxxxxxxxxxxx XXX (CEPO).

S2.2. XXXXXXXXX HORMONY A XXXXXX UVOLŇUJÍCÍ FAKTORY

S2.2.1 Xxxxxxx xxxxxxxxxxx xxxxxxxxxxx x mužů, mimo xxxx včetně:

• choriový xxxxxxxxxxxx (CG),

• xxxxxxxxxxxx xxxxxx (XX),

• xxxxxx xxxxxxxxxx xxxxxxxxxxxx (XxXX, xxxxxxxxxxx) a jeho xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, nafarelin x triptorelin),

 • xxxxxxxxxx x xxxx xxxxxxxxxxx xxxxxxx.

X2.2.2 Kortikotropiny x xxxxxx uvolňující faktory, xxxx. xxxxxxxxxxxx a xxxxxxxxxxxxx.

X2.2.3 Xxxxxxx xxxxxx (XX), xxxx xxxxxxx x xxxxxxxxx, xxxx xxxx včetně:

• xxxxxxx xxxxxxxxx hormonu, např. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx a xxxxxxxxxx,

• fragmenty xxxxxxxxx xxxxxxx, např. XXX-9604 x xXX 176–191.

X2.2.4 Xxxxxxx xxxxxxxxxx xxxxxxx xxxxxx, mimo jiné xxxxxx:

• xxxxxx xxxxxxxxxx xxxxxxx hormon (GHRH) x xxxx xxxxxxx, xxxx. XXX-1293, XXX-1295, xxxxxxxxxx a tesamorelin,

• xxxxxxxxxxx růstového hormonu (XXX) x xxxxxx xxxxxxxx [xxxx. xxxxxxxxxx, xxxxxxxxxxxx, ibutamoren (MK-677), xxxxxxxxxx, xxxxxxxxxxx (xxxxxxx), xxxxxxxxxxx x tabimorelin],

• xxxxxxx xxxxxxxxxx GH (XXXX) [xxxx. xxxxxxxxxxxx, xxxxxxxxxx (xxxxxxxxx), XXXX-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, GHRP-5 x XXXX-6].

X2.3. XXXXXXX XXXXXXX X MODULÁTORY RŮSTOVÝCH XXXXXXX

Xxxx xxxx včetně:

• xxxxxxxxxxxxx xxxxxxx faktory (XXX)

• xxxxxxxxxxxx xxxxxxx xxxxxx (HGF)

• růstový xxxxxx 1 xxxxxxx xxxxxxxx (IGF-1, xxxxxxxxxx) x xxxx xxxxxxx

• xxxxxxxxxx růstové xxxxxxx (XXX)

• xxxxxxx faktor xxxxxxxx x krevních xxxxxxxx (XXXX)

• xxxxxxxx-β4 x jeho deriváty, xxxx. XX-500

• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx faktor (XXXX)

x xxxxx xxxxxxx xxxxxxx xxxx modulátory xxxxxxxxx xxxxxxx ovlivňující xxxxxxx/xxxxxxxxx xxxxxxxx xx xxxxxxx, xxxxxxxx nebo vazech, xxxxxxxxxxxxx, využití energie, xxxxxxxxxxxxx kapacitu nebo xxxxxxxxxxx xxxx svalových xxxxxx.

X3 XXXX-2 XXXXXXXX

XXXXXXXX XXXXX (XXX SOUTĚŽI X MIMO XXXXXX)

Xxxxxxx xxxxxxxx xxxxx v xxxx xxxxx xxxx Xxxxxxxxxx látky.

Všichni xxxxxxxxxx x xxxxxxxxxxxx xxxx-2 xxxxxxxx xxxxxx xxxxx xxxxxxxxx xxxxxxx xxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

XXXXXXX

• Inhalační salbutamol: xxxxxxxxx 1600 mikrogramů xx 24 hodin x oddělených xxxxxxx, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 xxxxx xx jakékoliv dávce;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx;

• inhalační xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx;

• xxxxxxxxx vilanterol: xxxxxxxxx 25 xxxxxxxxxx xx 24 hodin.

POZNÁMKA

Přítomnost salbutamolu x xxxx x xxxxxxxx vyšším xxx 1000 ng/ml xxxx xxxxxxxxxxx v xxxxxxxx xxxxxx xxx 40 xx/xx neodpovídá xxxxxxxxxxxxxx xxxxxxx xxxxx x xxxx xxxxxxxxxx xx Xxxxxxxxx laboratorní xxxxx (XXX), pokud Xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, že xxxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx xxxxx (xxxxxxxxx) xx xx výše xxxxxxx xxxxxxxxx dávky.

S4 XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

XXXXXXXX STÁLE (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxxx xxxxx xx xxxxxxx X4.1 a X4.2 xxxx Specifické xxxxx.

Xxxxx xxxxxxxx xx xxxx X4.3 x X4.4 jsou Nespecifické xxxxx.

Xxxxxxxxxxx hormonové a xxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.

X4.1. XXXXXXXXXX XXXXXXXX

Xxxx xxxx včetně:

•	2-androstenol (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx)
•	2-xxxxxxxxxxx (5ɑ-androst-2-en-17-on)		•	androsta-3,5-dien-7,17-dion (xxxxxxxxx)
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	4-xxxxxxxxx-3,6,17 trion (6-xxx)		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx

X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX X XXXXXXXXXX XXXXXXXXXX XXXXXXXXXXXXX XXXXXXXXX (XXXXX)]

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

X4.3. XXXXX XXXXXXXXXXX XXXXXXXX RECEPTORU XXXXXXXX XXX

Xxxx xxxx včetně:

•	protilátky xxxxxxxxxxxxxx xxxxxxx X		•	xxxxxxxxxx xxxxxxxxxx, xxxx.:
•	xxxxxxxxxx xxxxxxxxx xxxxxxxx IIB, např.:			- xxxxx snižující xxxx xxxxxx xxxxxxx myostatinu
	- xxxxxxx xxxxxxxxx xxxxxxxx (xxxx. XXX-031)			- xxxxxxxx xxxxxx xxxxxxxxx (xxxx. xxxxxxxxxxx, propeptid xxxxxxxxxx)
•	xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx XXX (např. bimagrumab)			- xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx prekurzory (xxxx. xxxxxxxxxxx, xxxxxxx zumab, xxxxxxxxxxxxx, xxxxxxxxxx)

X4.4. XXXXXXXXXXX XXXXXXXXXX

X4.4.1 xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. XXXXX, agonisté peroxizomovými xxxxxxxxxxx aktivovaného xxxxxxxxx xxxxx (PPARδ), např. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) xxxxxxxx xxxxxx (XX1516, XX501516) x agonisté Xxx-xxxɑ , xxxx. XX9009, XX9011

X4.4.2 xxxxxxxx x xxxxxxxx xxxxxxxx

X4.4.3 xxxxxxxxx

X4.4.4 xxxxxxxxxxxx

X5 XXXXXXXXX X XXXXXXXXX XXXXX

XXXXXXXX STÁLE (XXX XXXXXXX I XXXX SOUTĚŽ)

Všechny xxxxxxxx xxxxx x této xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx diuretika x xxxxxxxxx xxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- a x-, xxxx xxxxxxxx.

Xxxx xxxx včetně:

•  Xxxxxxxxx, xxxx např.:

acetazolamid; amilorid; xxxxxxxxx; kanrenon; chlortalidon; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxx; metolazon; xxxxxxxxxxxxx; xxxxxxxx, např. bendroflumethiazid, xxxxxxxxxxxxx x xxxxxxxxxxxxxxxxxx; xxxxxxxxx; triamteren;

• Xxxxxxx, xxxx. konivaptan, xxxxxxxxxx, xxxxxxxxx;

• Plazmatické expandéry xxxxxxxx intravenózně, xxxx.:

xxxxxxx, xxxxxxx, xxxxxxxxxxx xxxxx, xxxxxxxx;

• Xxxxxxxxxxx;

• Xxxxxxxxxx;

x xxxxx látky s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

XXXXXXX

• xxxxxxxxxxx; pamabrom; x xxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxxx);

• xxxxxxx podání xxxxxxxxxxx x xxxxx xxxxxxxxx.

XXXXXXXX

Xxxxx xxxxxxxxxxx množství xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx: x xxxxxxxxxxx, xxxxxxxxxxx, katinu, xxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxx xx Vzorku Xxxxxxxxx xxxxxxxx nebo xxxxxxxx Xxx Xxxxxxx xx xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx (xxxxx xxxxxxxxx xxxxxx podání xxxxxxxxxx xxxxxxxxxxxxxx nebo lokálního xxxxxx xxxxxxxxxxx v xxxxxxxx anestezii), bude xxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx výjimku (XX) xx xxxx xxxxx xxxxx x xx, xxxxx xxx xxxx xxxxxxx na xxxxxxxxxx nebo xxxxx xxxxxxxxx látku.

ZAKÁZANÉ XXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxxx v xxxx xxxxx jsou Xxxxxxxxxxxx s xxxxxxxx xxxxx x M2.2, xxx xxxx Xxxxxxxxxx xxxxxx.

X1. XXXXXXXXXX X XXXX A KREVNÍMI XXXXXXXXXXXX

Xxxxxxxx xx následující:

M1.1. Xxxxxx xxxx xxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, allogenní (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxx x xxxxxxxxx xxxxxxx jakéhokoliv xxxxxx do xxxxxxxxx xxxxxxx x xxxxxxxx xxxxxxxx xxxxxx xxxx xxxxxx xxxxxx Sportovci xxxxxxxxxxxxxxx plazmaferézy xxxxxxxxx x registrovaném odběrovém xxxxxx.

X1.2. Xxxxx xxxxxxxxx xxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxx jiné xxxxxx:

Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (XXX13); xxxxxxxxx a xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, xxxx. xxxxxx náhražky xx xxxx hemoglobinu a xxxxxxxxxxxxxxxx xxxxxxxxxxxxx produkty, x xxxxxxxx xxxxxxxxxxx xxxxxxx inhalací.

M1.3. Xxxxxxxxx xxxxx intravaskulární manipulace x xxxx xxxx x xxxxxxxx komponentami xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX A XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X2.1. Xxxxxxxxx xxxx Xxxxx x xxxxxx xx xxxxxx xxxxxxx xxxxxxxxx x platnost Xxxxxx odebraných xxx Xxxxxxxxx kontrole.

Mimo jiné xxxxxx:

Xxxxxx x/xxxx úprava Xxxxxx, např. xxxxxxxx xxxxxxx xx Vzorku.

M2.2. Xxxxxxxxxx infuze x/xxxx xxxxxxx více xxx xxxxxx 100 xx xx 12 hodin xxxxx xxxxxx xxxxxxxxx xxxxxxxxx v průběhu xxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxxx xxxxxxx xxxx klinických xxxxxxxxxxxxxx xxxxxxxxx.

X3. GENOVÝ X XXXXXXX XXXXXX

X xxxxxx xxxxxxxxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:

X3.1. Xxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx analogů, které xxxxx xxxxxx sekvence xxxxxx x/xxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxx. Xx xxxx xxxx xxxxxxxx xxxxxxxxxxx úprav xxxx, umlčování xxxx x xxxxxxxxxxx přenosů xxxx.

X3.2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.

X6 STIMULANCIA

ZAKÁZANÉ XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx xxxxx x výjimkou xxxxx xxxxxxxxx x X6.X, xxx jsou Nespecifické xxxxx.

Xxxxxxxx xxxxx x xxxx sekci: xxxxxx x metylendioxymetamfetamin (MDMA/„extáze“)

Všechna xxxxxxxxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- a x-, xxxx xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

X6.X: XXXXXXXXXXXX XXXXXXXXXXX

•	xxxxxxxxx		•	xxxxxxxxxxxx [4-fenylpiracetam (xxxxxxxx)]
•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxx(x-)
•	xxxxxxxxx		•	x-xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx
•	xxxxxxxxxxx

Xxxxxxxxx, xxxxx xxxx xxxxxxxx uveden x xxxxx oddíle, xx Xxxxxxxxxxx látkou.

S6.B: XXXXXXXXXX XXXXXXXXXXX

Xxxx jiné xxxxxx:

•	2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, XXXXX)		•	xxxxxxxxxxx		•	xxxxxxxxx
•	3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx		•	xxxxxxxxx (xxxxxxxxxxxxx)
•	4-xxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxx
•	4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, metylhexanamin)		•	heptaminol		•	pentetrazol
•	4-methylpentan-2-amin (1,3-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxx (xxxxxxxxx)		•	xxxxxxxxxxx x jeho xxxxxxxx
•	5-xxxxxxxxxx-2-xxxx (1,4-dimetylamylamin, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX)		•	xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxx1)		•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxx x xxxx xxxxxxx, xxxx. xxxxxxxx, xxxxxxxx x ɑ-xxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx2)
•	xxxxxxxxxxxxxx (dimetylamfetamin)		•	metylendioxymetamfetamin		•	selegilin
•	efedrin3)		•	metylefedrin3)		•	sibutramin
•	epinefrin (xxxxxxxxx)4)		•	xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx]		•	xxxxxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx)
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxx (1,5-xxxxxxxxxxxxxxxx)

x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx

XXXXXXX

• xxxxxxxx;

• xxxxxxxx xxxxxxxxxxx x xxxxxxx jejich xxxxxxx, xxxxxxx, xxxxxx xxxx xxxxxx xxxxxxx (např. xxxxxxxxxx, klonazolin, fenoxazolin, xxxxxxxxxxx, nafazolin, oxymetazolin, xxxxxxxxxx, tramazolin, xylometazolin) x xxxxxxxxxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2024⁵⁾.

X7 XXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx zakázané látky x xxxx xxxxx xxxx Specifické látky.

Návykové xxxxx v xxxx xxxxx: xxxxxxxxx (xxxxxx)

Xxxxxxxxxxx xxxxxxxxx, xxxxxx jejich xxxxxxxxxx všech xxxxxxxxx xxxxxxx, např. x- x x, jsou xxxxxxxx.

•	xxxxxxxxxxx		•	xxxxxxxx x xxxx xxxxxxxx		•	xxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx
•	xxxxxxxxx (xxxxxx)		•	xxxxxxx		•	xxxxxxxx		•	xxxxxxxx
						•	xxxxxxxxx

X8 XXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx zakázané xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx. Návykové xxxxx x této sekci: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx xxxxxxxx x syntetické xxxxxxxxxxx xxxx xxxxxxxx, xxxx.

• x konopí (hašiš, xxxxxxxxx) x xxxxxxxxx xxxxxxxxxx

• xxxxxxxx a xxxxxxxxxx tetrahydrokanabionoly (XXX)

• xxxxxxxxxx xxxxxxxxxxx napodobující xxxxxx XXX

XXXXXXX

• kanabidiol

S9 XXXXXXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx v xxxx xxxxx jsou Xxxxxxxxxx xxxxx.

Xxxxxxx glukokortikoidy xxxx zakázány, pokud xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, xxxxxxxxx [xxxxxx xxxxxxxxxx (xxxx. xxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx)] nebo xxxxxxxx xxxxxx.

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxxx xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxxxxx

XXXXXXXX

• Jiné xxxxxxx podání (včetně xxxxxxxxxxx x xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, dermálního, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, xxxxxx x xxxxxxxxxxxx) xxxxxx xxxxxxxx, xxxxx xx xxxxxxxxx x rámci xxxxxxxx xxxxxxxxxxxx dávek a xxxxxxxxxxxxxx xxxxxxxx.

X1 BETA-BLOKÁTORY

ZAKÁZANÉ X URČITÝCH SPORTECH

Všechny xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx.

Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx v xxxxxxxxxxxxx xxxxxxxx Při Xxxxxxx x xxx xx xx xxxxxxxx xxxxxxxx (*) x Xxxx xxxxxx.

• xxxxxxxxxxx (XX)*

• lyžování/snowboarding (XXX) – xxxxx xx xxxxxx, akrobatické skoky / U-rampa x xxxxxxxxx U-rampa / xxx air

• automobilový xxxxx (XXX)

• podvodní xxxxxx (XXXX)* v xxxxxxxxxxxx xxxxxxx xxxxxxxx, xxxx harpunou a xxxxxxx na xxxx

• xxxxxxxx (všechny disciplíny) (XXXX)

• xxxxx (WDF)

• xxxx (IGF)

• xxxxxxxx (XXX)

• xxxxxxx (XXXX, XXX)*

* xxxxxxxx xxxx Xxxx xxxxxx

Xxxx xxxx xxxxxx:

•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxx
•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxx

Xxxxxxx x. 2

Znění xxxxxxxxxxx smlouvy x xxxxxxxxx xxxxxx
&xxxx;

¹⁾ xxxxx (x-xxxxxxxxxxxxxxxx) x xxxx x-xxxxxx: je xxxxxxxx xxxxx xxx xxxxxxxxxxx x moči xxxxx xxx 5 xxxxxxxxxx x 1 xx.

²⁾ xxxxxxxxxxxxx: zakázaný pouze xxx koncentraci x xxxx xxxxx xxx 150 mikrogramů v 1 ml.

³⁾ xxxxxxx x xxxxxxxxxxxx: xxxxxxxx xxx koncentraci v xxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx.

⁴⁾ xxxxxxxxx (xxxxxxxxx): xxxx xxxxxxxx xxxxxxx podávání, např. xxxxx, xxxx, xxxx xxxxxxxx podávání s xxxxxxxxx xxxxxxxxxx.

⁵⁾ xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, pipradrol x xxxxxxxx: xxxx látky xxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2024 x xxxxxx považovány xx Xxxxxxxx látky.

Informace

Právní xxxxxxx x. 19/2025 Sb. xxxxx xxxxxxxxx xxxx 28.1.2024.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx není xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx předpisu